Scroll To Top
News

Is There a New Superdrug on the Way?

Is There a New Superdrug on the Way?

Superpill_0

In summer 2006 the Food and Drug Administration approved Atripla, the first single-pill treatment containing a full three-drug antiretroviral regimen. While a boon to many, the Sustiva component of the combo pill kept it from a sizable number of HIVers, including pregnant women, people unable to handle Sustiva's central nervous system side effects, and African-Americans, who have been shown in studies to metabolize Sustiva too slowly. Now drugmaker Gilead Sciences is planning clinical trials of a Sustiva-free alternative: Quad, a four-in-one combination pill some have already dubbed an anti-HIV 'superdrug.' Quad combines Gilead's nucleoside analogs Emtriva and Viread with the company's experimental integrase inhibitor, elvitegravir, and a booster medication. 'If Sustiva isn't useful, Quad may be of more benefit,' Gilead president John Milligan said of the new four-in-one pill. The company hopes to begin safety trials of Quad in the second half of the year.

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.